Current Report Filing (8-k)
August 14 2018 - 8:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 14, 2018
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-34655
|
|
04-3581650
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
One Broadway, 14th Floor
Cambridge, Massachusetts
|
|
02142
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area
code: (617) 588-1960
Check the appropriate box below
if the
Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12 under
the
Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications
pursuant to
Rule 14d-2(b) under
the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications
pursuant to
Rule 13e-4(c) under
the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 8.01. Other Events.
On August 14, 2018, AVEO Pharmaceuticals, Inc. (the Company) issued a press release announcing that the China National Drug Administration has
accepted an investigational new drug application of CANbridge Life Sciences for a Phase 1b/III clinical trial of CAN017 in esophageal squamous cell cancer. CAN017, which the Company refers to as AV-203, is the Companys clinical-stage ErbB3
(HER3) inhibitory antibody product candidate. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on
Form 8-K.
The
information contained therein is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
AVEO Pharmaceuticals, Inc.
|
Date: August 14, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Michael Bailey
|
|
|
|
|
|
|
Michael Bailey
|
|
|
|
|
|
|
President and Chief Executive Officer
|
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jun 2024 to Jul 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jul 2023 to Jul 2024